FDA Clears Subcutaneous SKYRIZI for Crohn's Disease Induction Treatment

The FDA has approved AbbVie's subcutaneous induction regimen for SKYRIZI (risankizumab) to treat Crohn's disease. This allows patients to initiate treatment at home using an on-body injector, eliminating the need for intravenous infusions. The approval follows Phase 3 AFFIRM trial data, which showed 74% of biologic-naive patients achieved clinical remission at week 12 with the subcutaneous method.